In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
about
Prediction of Cancer Drug Resistance and Implications for Personalized MedicinePersonalized chemotherapy profiling using cancer cell lines from selectable miceERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assayPrediction of individual response to anticancer therapy: historical and future perspectivesDrug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cellsMicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasEvaluation of the chemosensitivity of primary cultured malignant melanoma cells using the collagen gel droplet-embedded culture drug sensitivity testDrug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial)Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancerSERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.Systemic therapy of non-resectable metastatic melanoma.Peek before you treat? Is it a fantasy or reality?Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.Multiplexed Dosing Assays by Digitally Definable Hydrogel Volumes.Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvementTargeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.Establishment of a primary pleomorphic xanthoastrocytoma cell line: in vitro responsiveness to some chemotherapeutics.Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration.Q56897624Selective regional perfusion of the bilateral external carotid arteries with pegylated liposomal doxorubicin and melphalan to treat metastatic malignant melanoma of the scalp
P2860
Q26770581-06356D30-EAE1-4B13-B1A6-16D4A80042C0Q30538234-7E497AC4-787B-44B0-A868-593E28FBABE9Q33327609-84555175-6C2B-42C1-8805-EA74ADCF8AC7Q33807207-1F9CD529-9CBB-4AFF-889A-A52CAB20D343Q34795754-E8B3575F-6C6D-4B1E-BEE9-663932FC6DDEQ35024682-47E6DDE4-47D8-47C5-A111-CD7658383B90Q35678181-CD834159-2F49-4199-B2F4-FD9ACBC41462Q35766816-0B079E80-29E9-4C52-B5D3-E6C146BB7CB8Q35845352-9D9C5122-4C0F-48C8-8686-085CB4869781Q36375337-E592A13E-8535-4985-9652-531FD08BC27FQ36406956-B0F95E78-0D2F-43DA-A672-0D827812C66FQ36610620-7A8844A4-2081-499E-9BE4-98CAF72F05FEQ36778096-7635F35F-C286-47E9-9D5A-503B0841DC36Q36859193-C8C8A16F-CE1C-4861-834E-8F13AA686F25Q36962895-1FCD6945-7A46-4F9C-9FF7-96BC71504330Q37888461-4368B597-2621-4346-BA58-B172E30F0397Q38166572-0DFE9079-50A4-47FB-8953-3DFE2790D7A0Q38364708-B2E3F210-CE92-4B16-959D-B3715EA250F4Q38737031-05E6E390-BBDE-49DD-B341-99103620E0DCQ38815777-89E03919-362C-4A27-AA83-11BC6DE9376BQ38842969-0E438371-07E0-451B-8FF8-918C0953EF38Q38852335-72CFBE8A-7ED4-4BDE-8E6C-4D69F294B832Q39532769-2561CB4C-F2CD-45B4-93A0-5DE3860B9D22Q47136600-338B714B-3A4D-4065-9055-CF5F850D3C2CQ51061357-7FA4144D-FD56-40FF-AA18-B19692224AF0Q53266946-DDC1CE6B-7C9C-488D-8E2D-D53830AEBDF5Q56897624-6317C4CD-262D-407D-89DF-D988ACEE8A8FQ58493991-4F9F5437-5FB0-4DBE-A6EB-9C3501C63FE9
P2860
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@en
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@nl
type
label
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@en
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@nl
prefLabel
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@en
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@nl
P2093
P50
P1476
In vitro drug sensitivity pred ...... ic Cooperative Oncology Group.
@en
P2093
Adina Thoelke
Axel Hauschild
Claudia Pföhler
Dermatologic Cooperative Oncology Group
Jens Ulrich
Karsten Neuber
Konstanze Spieth
Martin Kaatz
Uwe Reinhold
Werner Rittgen
P304
P356
10.1158/1078-0432.CCR-05-2763
P407
P577
2006-09-01T00:00:00Z